Moderna looks to new COVID booster, RSV shot to curb falling sales

Moderna Looks To New COVID Booster, RSV Shot To Curb Falling Sales

2 weeks from now

Aug 3, 2023  · Sales of the company’s COVID-19 vaccine plummeted 94% year over year. But executives believe newer products can help revenue rebound. ... Moderna looks to new …

biopharmadive.com

Pfizer, GSK, Moderna Struggle In A Shrinking RSV Vaccine Market

2 weeks from now

In its Q3 results, GSK , the first to receive U.S. approval for an RSV vaccine in May 2023, said its Arexvy vaccine added £188M in sales, indicating ~ a 73% YoY drop.

msn.com

Moderna Reports Surprise Profit And Sets Out Plan For RSV Vaccine

2 weeks from now

Feb 22, 2024  · Focus on new treatments as Covid vaccine sales fell from $18.4 billion in 2022 to $6.8 billion last year A dose of Moderna's spikevax autumn Covid booster vaccination. …

irishtimes.com

Moderna's Stock Falls After Data Shows Biotech's RSV Vaccine Trails ...

2 weeks from now

Jun 26, 2024  · Moderna's stock was on track for its biggest one-day percentage decline since Dec. 27 of 2022, when it fell 9.5%. The stock is down 12.6% in the month to date, but is still up …

morningstar.com

Moderna Reports Surprise Profit, Sets Out Road Map For RSV …

2 weeks from now

Feb 22, 2024  · The company reaffirmed its 2024 forecast of $4 billion in sales, the lowest figure for annual revenue since its COVID vaccine got U.S. emergency authorization in late 2020.

usnews.com

Moderna Expects CDC To View Its RSV Vaccine As Equal To Rival Shots

2 weeks from now

May 2, 2024  · Moderna shares jumped more than 7% in early trading after the company said it expects "a parity recommendation" to Pfizer's , opens new tab and GSK's , opens new tab …

reuters.com

Moderna Pitches RSV Shot, New Vaccines After ‘difficult Year Of ...

2 weeks from now

Feb 22, 2024  · Dive Brief: Moderna shares rose by as much as 10% Thursday morning after the COVID-19 vaccine developer reported fourth quarter profit that beat Wall Street expectations …

biopharmadive.com

Moderna Reports Surprise Profit, Sets Out Road Map For RSV Vaccine

2 weeks from now

Feb 22, 2024  · The Cambridge, Massachusetts-based drugmaker reported fourth quarter sales of $2.8 billion from its COVID vaccine, its only commercial product, down 43% from 2022 but in …

reuters.com

What’s Behind The Recent Rise In MRNA Stock? - Forbes

2 weeks from now

6 days ago  · Moderna has been struggling amid its falling sales post the pandemic. For perspective, Moderna’s revenue plunged 64% y-o-y to $6.8 billion in 2023 due to lower …

forbes.com

Moderna Says Its RSV Shot Is 50% Effective Across A Second Season

2 weeks from now

NEW YORK, June 26 (Reuters) - Moderna Inc , opens new tab respiratory syncytial virus (RSV) shot mRESVIA showed 50% efficacy in preventing RSV after 18 months, the drugmaker said …

reuters.com